Uno studio clinico sulle combinazioni di trattamento a base di derutecan ifinatamab o come monoterapia per trattare il carcinoma della prostata resistente al castrato metastatico (MCRPC) (MK-2400-01A/IDEATE-PROSTATE02)
MK-2400-01A SOPDUTY: un ombrello 1/2 di fase 1/2, un protocollo principale MK-2400-U01 per valutare la sicurezza e l'efficacia delle combinazioni di trattamento a base di prostate di derutecan IfinataMab (IDeataMate02) o Ideatate02) di IdeataMab Deruxtecan da solo nei partecipanti al carcinoma prostatico a base di castrazione metastatica (MCRPC) (IDeatate02)
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about:
- The safety of the study treatment and if people tolerate it.
- A safe dose level of I-DXd that can be used with other treatments.
- Participant levels of prostate specific antigen (PSA) during treatment.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This sub study MK-2400-01A assesses treatments for metastatic castration-resistant prostate cancer (mCRPC).
The master screening protocol is MK-2400-U01
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Toll Free Number
- Numero di telefono: 1-888-577-8839
- Email: Trialsites@msd.com
Luoghi di studio
-
-
-
La Rioja, Argentina, F5300COE
- Reclutamento
- Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0200)
-
Contatto:
- Study Coordinator
- Numero di telefono: 54-380-443-6443
-
-
Buenos Aires
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1426ANZ
- Reclutamento
- Instituto Alexander Fleming ( Site 0202)
-
Contatto:
- Study Coordinator
- Numero di telefono: 5411 3221 8900
-
-
-
-
New South Wales
-
Macquarie University, New South Wales, Australia, 2109
- Reclutamento
- Macquarie University-MQ Health Clinical Trials Unit ( Site 0801)
-
Contatto:
- Study Coordinator
- Numero di telefono: +61 2 9812 2956
-
-
-
-
-
São Paulo, Brasile, 01221-020
- Reclutamento
- IPITEC ( Site 0275)
-
Contatto:
- Study Coordinator
- Numero di telefono: +551194322-6006
-
São Paulo, Brasile, 03102-006
- Reclutamento
- IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0269)
-
Contatto:
- Study Coordinator
- Numero di telefono: +551144500360
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brasile, 59062-000
- Reclutamento
- Liga Norte Riograndense Contra o Câncer ( Site 0271)
-
Contatto:
- Study Coordinator
- Numero di telefono: (84) 4009-5595
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasile, 90035-001
- Reclutamento
- Hospital Moinhos de Vento ( Site 0278)
-
Contatto:
- Study Coordinator
- Numero di telefono: +55 51 3314-3209
-
Porto Alegre, Rio Grande do Sul, Brasile, 90020-090
- Reclutamento
- Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0270)
-
Contatto:
- Study Coordinator
- Numero di telefono: +555132148151
-
-
São Paulo
-
Bragança Paulista, São Paulo, Brasile, 12916-542
- Reclutamento
- Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0268)
-
Contatto:
- Study Coordinator
- Numero di telefono: +551124901366
-
Ribeirão Preto, São Paulo, Brasile, 14048900
- Reclutamento
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP) ( Site 0273)
-
Contatto:
- Study Coordinator
- Numero di telefono: (16) 3963-6487
-
São José do Rio Preto, São Paulo, Brasile, 15090-000
- Reclutamento
- Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0263)
-
Contatto:
- Study Coordinator
- Numero di telefono: +55 17 99625-3919
-
São Paulo, São Paulo, Brasile, 01327-001
- Reclutamento
- Hospital Alemao Oswaldo Cruz ( Site 0279)
-
Contatto:
- Study Coordinator
- Numero di telefono: 55 11 3549-0009
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Reclutamento
- BC Cancer - Vancouver Center ( Site 0103)
-
Contatto:
- Study Coordinator
- Numero di telefono: 6048776000
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Reclutamento
- Sunnybrook Research Institute ( Site 0109)
-
Contatto:
- Study Coordinator
- Numero di telefono: 4164806100
-
Toronto, Ontario, Canada, M5G 2M9
- Reclutamento
- Princess Margaret Cancer Centre ( Site 0102)
-
Contatto:
- Study Coordinator
- Numero di telefono: 4169464501
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Reclutamento
- Jewish General Hospital ( Site 0108)
-
Contatto:
- Study Coordinator
- Numero di telefono: 5143408110
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Reclutamento
- CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0107)
-
Contatto:
- Study Coordinator
- Numero di telefono: 8197802222
-
-
-
-
Maule Region
-
Talca, Maule Region, Chile, 3465584
- Reclutamento
- Clinica Universidad Catolica del Maule ( Site 0236)
-
Contatto:
- Study Coordinator
- Numero di telefono: 56992992913
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chile, 8420383
- Reclutamento
- Bradfordhill ( Site 0231)
-
Contatto:
- Study Coordinator
- Numero di telefono: +56229490970
-
Santiago, Region M. de Santiago, Chile, 7560908
- Reclutamento
- Centro de Oncología de Precisión ( Site 0241)
-
Contatto:
- Study Coordinator
- Numero di telefono: +56225189885
-
Santiago, Region M. de Santiago, Chile, 7500921
- Reclutamento
- Fundación Arturo López Pérez ( Site 0232)
-
Contatto:
- Study Coordinator
- Numero di telefono: 56224205098
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Chile, 2520598
- Reclutamento
- ONCOCENTRO APYS ( Site 0234)
-
Contatto:
- Study Coordinator
- Numero di telefono: +56323320850
-
-
-
-
-
Seoul, Corea del Sud, 06351
- Reclutamento
- Samsung Medical Center ( Site 0926)
-
Contatto:
- Study Coordinator
- Numero di telefono: +82234103459
-
Seoul, Corea del Sud, 03722
- Attivo, non reclutante
- Severance Hospital Yonsei University Health System ( Site 0924)
-
-
Seoul
-
Songpagu, Seoul, Corea del Sud, 05505
- Reclutamento
- Asan Medical Center ( Site 0925)
-
Contatto:
- Study Coordinator
- Numero di telefono: +82230105977
-
-
-
-
Gironde
-
Bordeaux, Gironde, Francia, 33000
- Reclutamento
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 0498)
-
Contatto:
- Study Coordinator
- Numero di telefono: +33556333261
-
-
Nord
-
Lille, Nord, Francia, 59000
- Reclutamento
- Centre Oscar Lambret ( Site 0495)
-
Contatto:
- Study Coordinator
- Numero di telefono: +333 20 29 56 06
-
-
Pays de la Loire Region
-
Saint-Herblain, Pays de la Loire Region, Francia, 44800
- Reclutamento
- Institut De Cancerologie De L Ouest ( Site 0494)
-
Contatto:
- Study Coordinator
- Numero di telefono: +33240679900
-
-
Pyrenees-Atlantiques
-
Bayonne, Pyrenees-Atlantiques, Francia, 64100
- Reclutamento
- Centre Hospitalier de la Cote Basque ( Site 0496)
-
Contatto:
- Study Coordinator
- Numero di telefono: +33559443762
-
-
Rhone
-
Pierre-Bénite, Rhone, Francia, 69310
- Reclutamento
- centre hospitalier lyon sud ( Site 0497)
-
Contatto:
- Study Coordinator
- Numero di telefono: 33 4 78 86 43 24
-
-
-
-
-
Hamburg, Germania, 20246
- Reclutamento
- Universitaetsklinikum Hamburg-Eppendorf ( Site 0524)
-
Contatto:
- Study Coordinator
- Numero di telefono: +4915222815585
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Germania, 69120
- Reclutamento
- NCT ( Site 0528)
-
Contatto:
- Study Coordinator
- Numero di telefono: 00496221566857
-
Ulm, Baden-Wurttemberg, Germania, 89081
- Reclutamento
- Universitaetsklinikum Ulm. ( Site 0530)
-
Contatto:
- Study Coordinator
- Numero di telefono: +4973150058188
-
-
Thuringia
-
Jena, Thuringia, Germania, 07747
- Reclutamento
- Universitaetsklinikum Jena ( Site 0525)
-
Contatto:
- Study Coordinator
- Numero di telefono: +49-3641-9-329901
-
-
-
-
-
Dublin, Irlanda, D09 V2N0
- Reclutamento
- Beaumont Hospital, Dublin ( Site 0465)
-
Contatto:
- Study Coordinator
- Numero di telefono: 0035318092010
-
Dublin, Irlanda, D24 NR0A
- Reclutamento
- Tallaght University Hospital ( Site 0462)
-
Contatto:
- Study Coordinator
- Numero di telefono: 0035314144209
-
-
Dublin
-
Dublin, Dublin, Irlanda, D04 T6F4
- Reclutamento
- St Vincent's University Hospital ( Site 0463)
-
Contatto:
- Study Coordinator
- Numero di telefono: +353 1 221 4982
-
-
-
-
-
Haifa, Israele, 3109601
- Reclutamento
- Rambam Health Care Campus ( Site 0400)
-
Contatto:
- Study Coordinator
- Numero di telefono: 972(47776234)
-
Jerusalem, Israele, 9112001
- Reclutamento
- Hadassah Medical Center ( Site 0404)
-
Contatto:
- Study Coordinator
- Numero di telefono: +97226777333
-
Petah Tikva, Israele, 4941492
- Reclutamento
- Rabin Medical Center ( Site 0402)
-
Contatto:
- Study Coordinator
- Numero di telefono: +972544594048
-
Ramat Gan, Israele, 5265601
- Reclutamento
- Sheba Medical Center ( Site 0401)
-
Contatto:
- Study Coordinator
- Numero di telefono: +97235303030
-
Tel Aviv, Israele, 6423906
- Reclutamento
- Sourasky Medical Center ( Site 0403)
-
Contatto:
- Study Coordinator
- Numero di telefono: +97236947832
-
-
-
-
-
Brescia, Italia, 25123
- Attivo, non reclutante
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 0432)
-
Milan, Italia, 20133
- Reclutamento
- Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0431)
-
Contatto:
- Study Coordinator
- Numero di telefono: +390223904449
-
Naples, Italia, 80131
- Reclutamento
- A.O.U. Federico II di Napoli ( Site 0435)
-
Contatto:
- Study Coordinator
- Numero di telefono: +390817463660
-
Roma, Italia, 00168
- Reclutamento
- Fondazione Policlinico Universitario Agostino Gemelli ( Site 0433)
-
Contatto:
- Study Coordinator
- Numero di telefono: +390630155202
-
-
Torino
-
Orbassano, Torino, Italia, 10143
- Reclutamento
- AOU San Luigi Gonzaga di Orbassano ( Site 0434)
-
Contatto:
- Study Coordinator
- Numero di telefono: 00390119026534
-
-
-
-
-
Auckland, Nuova Zelanda, 1023
- Reclutamento
- Auckland City Hospital ( Site 0831)
-
Contatto:
- Study Coordinator
- Numero di telefono: +6493074949
-
-
-
-
Gelderland
-
Ede, Gelderland, Olanda, 6716 RP
- Reclutamento
- Ziekenhuis Gelderse Vallei ( Site 0683)
-
Contatto:
- Study Coordinator
- Numero di telefono: +31 318 435499
-
Nijmegen, Gelderland, Olanda, 6525 GA
- Reclutamento
- UMC St. Radboud ( Site 0679)
-
Contatto:
- Study Coordinator
- Numero di telefono: +31 24 361 1111
-
-
Provincie Friesland
-
Drachten, Provincie Friesland, Olanda, 9202 NN
- Reclutamento
- Nij Smellinghe ( Site 0684)
-
Contatto:
- Study Coordinator
- Numero di telefono: 0512 588 888
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Polonia, 60-355
- Reclutamento
- Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 0590)
-
Contatto:
- Study Coordinator
- Numero di telefono: +61 854 79 87
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polonia, 02-781
- Reclutamento
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0586)
-
Contatto:
- Study Coordinator
- Numero di telefono: +48 22 546 33 81
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Polonia, 80-214
- Reclutamento
- Uniwersyteckie Centrum Kliniczne ( Site 0588)
-
Contatto:
- Study Coordinator
- Numero di telefono: +48 58 584 44 66
-
-
West Pomeranian Voivodeship
-
Koszalin, West Pomeranian Voivodeship, Polonia, 75-581
- Reclutamento
- Szpital Wojewódzki im. M.Kopernika Oddział Onk. Klinicznej z Pododdziałem Chemioterapii Jednodniowej ( Site 0587)
-
Contatto:
- Study Coordinator
- Numero di telefono: +48943488930
-
-
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Regno Unito, CB2 2QQ
- Reclutamento
- Addenbrooke's Hospital ( Site 0747)
-
Contatto:
- Study Coordinator
- Numero di telefono: 00441223216083
-
-
London, City of
-
London, London, City of, Regno Unito, NW3 2QG
- Reclutamento
- Royal Free Hospital ( Site 0743)
-
Contatto:
- Study Coordinator
- Numero di telefono: 00442077940500/2237
-
London, London, City of, Regno Unito, EC1A 7BE
- Reclutamento
- St Bartholomew's Hospital ( Site 0749)
-
Contatto:
- Study Coordinator
- Numero di telefono: 00442073777000
-
-
Surrey
-
London, Surrey, Regno Unito, SM3 5PT
- Reclutamento
- Royal Marsden Hospital (Sutton) ( Site 0741)
-
Contatto:
- Study Coordinator
- Numero di telefono: 0203 437 3500
-
-
-
-
-
Madrid, Spagna, 28034
- Reclutamento
- Hospital Universitario Ramon y Cajal ( Site 0620)
-
Contatto:
- Study Coordinator
- Numero di telefono: +34913368263
-
Madrid, Spagna, 28041
- Reclutamento
- Hospital Universitario 12 de Octubre ( Site 0622)
-
Contatto:
- Study Coordinator
- Numero di telefono: +34608464547
-
Madrid, Spagna, 28040
- Reclutamento
- Hospital Clinico San Carlos ( Site 0618)
-
Contatto:
- Study Coordinator
- Numero di telefono: +34913303546
-
Seville, Spagna, 41013
- Reclutamento
- Hospital Universitario Virgen del Rocio ( Site 0619)
-
Contatto:
- Study Coordinator
- Numero di telefono: +34955013068
-
-
Barcelona
-
L Hospitalet Del Llobregat, Barcelona, Spagna, 08908
- Reclutamento
- ICO L Hospitalet ( Site 0617)
-
Contatto:
- Study Coordinator
- Numero di telefono: +34932607744
-
-
-
-
California
-
Los Angeles, California, Stati Uniti, 90095
- Reclutamento
- UCLA Hematology & Oncology ( Site 0003)
-
Contatto:
- Study Coordinator
- Numero di telefono: 310-829-5471
-
Orange, California, Stati Uniti, 92868
- Reclutamento
- University of California-Irvine Medical Center ( Site 0016)
-
Contatto:
- Study Coordinator
- Numero di telefono: 714-456-5153
-
San Francisco, California, Stati Uniti, 94158
- Reclutamento
- UCSF Medical Center at Mission Bay ( Site 0034)
-
Contatto:
- Study Coordinator
- Numero di telefono: 415-502-2097
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20010
- Reclutamento
- MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026)
-
Contatto:
- Study Coordinator
- Numero di telefono: 202-877-3061
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- Reclutamento
- University of Michigan ( Site 0021)
-
Contatto:
- Study Coordinator
- Numero di telefono: 734-936-4000
-
-
New York
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- Memorial Sloan Kettering Cancer Center ( Site 0006)
-
Contatto:
- Study Coordinator
- Numero di telefono: 347-798-8620
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- Reclutamento
- UPMC Hillman Cancer Center ( Site 0014)
-
Contatto:
- Study Coordinator
- Numero di telefono: 412-647-2811
-
-
Tennessee
-
Germantown, Tennessee, Stati Uniti, 38138
- Reclutamento
- The West Clinic, PLLC dba West Cancer Center ( Site 0005)
-
Contatto:
- Study Coordinator
- Numero di telefono: 901-683-0055
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98109
- Reclutamento
- Fred Hutchinson Cancer Center ( Site 0013)
-
Contatto:
- Study Coordinator
- Numero di telefono: 206-288-1111
-
-
-
-
-
Taichung, Taiwan, 40705
- Reclutamento
- Taichung Veterans General Hospital ( Site 0902)
-
Contatto:
- Study Coordinator
- Numero di telefono: +886423592525
-
Taipei, Taiwan, 11217
- Reclutamento
- Taipei Veterans General Hospital ( Site 0901)
-
Contatto:
- Study Coordinator
- Numero di telefono: +886228712121
-
-
-
-
-
Adana, Turchia (Türkiye), 01250
- Reclutamento
- Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0650)
-
Contatto:
- Study Coordinator
- Numero di telefono: +903223271274
-
Ankara, Turchia (Türkiye), 06230
- Reclutamento
- Hacettepe Universitesi Tip Fakultesi ( Site 0648)
-
Contatto:
- Study Coordinator
- Numero di telefono: +90 312 305 50 00
-
Ankara, Turchia (Türkiye), 06800
- Reclutamento
- Ankara Bilkent Şehir Hastanesi ( Site 0654)
-
Contatto:
- Study Coordinator
- Numero di telefono: +903125526000
-
Ankara, Turchia (Türkiye), 06620
- Reclutamento
- Ankara Universitesi Tip Fakultesi Hastanesi ( Site 0653)
-
Contatto:
- Study Coordinator
- Numero di telefono: +903122126040
-
Istanbul, Turchia (Türkiye), 34010
- Reclutamento
- Koç Üniversitesi Hastanesi ( Site 0656)
-
Contatto:
- Study Coordinator
- Numero di telefono: +905369410661
-
Istanbul, Turchia (Türkiye), 34098
- Reclutamento
- Istanbul Universitesi Cerrahpasa ( Site 0649)
-
Contatto:
- Study Coordinator
- Numero di telefono: +902124143000
-
Rize, Turchia (Türkiye), 53020
- Reclutamento
- Recep Tayyip Erdogan University Training and Research Hospital ( Site 0655)
-
Contatto:
- Study Coordinator
- Numero di telefono: +904642130491
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
- Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months before Screening
- Has current evidence of distant metastatic disease
- Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after treatment
- Participants receiving bone resorptive therapy (including, but not limited to bisphosphonate or denosumab) must have been on stable doses for ≥4 weeks before allocation/randomization
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 10 days before allocation/randomization
- Has prior treatment with poly-ADP-ribose polymerase inhibitors (PARPi) if indicated by local approved regimen or were deemed ineligible to receive PARPi by the investigator
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use (except for a history of radiation pneumonitis that did not require steroids), current ILD, clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out
- Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
- Uncontrolled or significant cardiovascular disease
- History of pituitary dysfunction
- Poorly controlled diabetes mellitus
- History or current condition of adrenal insufficiency (eg, Addison's disease)
- Has received prior treatment with taxane-based chemotherapy agent for metastatic castration-resistant prostate cancer (mCRPC).
- Chronic steroid treatment (dose of >10 mg daily prednisone equivalent), except for low-dose inhaled steroids (for asthma/chronic obstructive pulmonary disease), topical steroids (for mild skin conditions), or intra-articular steroid injections
- Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Active autoimmune disease that has required systemic treatment in the past 2 years
- History of allogeneic tissue/solid organ transplant
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Docetaxel
Participants will receive docetaxel at a determined dose every 3 weeks (Q3W) for a maximum of 10 cycles. Each cycle is 21 days. |
Administered via Intravenous (IV) infusion at a specified dose on specified days |
|
Sperimentale: Ifinatamab Deruxtecan (I-DXd)
Participants will receive I-DXd at a determined dose Q3W until unacceptable toxicity, progressive disease (PD), death or withdrawal of consent. |
Administered via IV infusion at a specified dose on specified days
Altri nomi:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. |
|
Sperimentale: I-DXd + Opevesostat
Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS opevesostat at a determined dose until any of the criterion for discontinuation of study intervention is met. |
Administered via IV infusion at a specified dose on specified days
Altri nomi:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. Administered orally at a specified dose on specified days
Altri nomi:
|
|
Sperimentale: I-DXd +ARPI (Abiraterone or Enzalutamide)
Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS ARPI (Androgen Receptor Pathway Inhibitor) - Abiraterone acetate OR Enzalutamide at a determined dose until any of the criterion for discontinuation of study intervention is met. |
Administered via IV infusion at a specified dose on specified days
Altri nomi:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. Administered orally at a specified dose on specified days Administered orally at a specified dose on specified days |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Efficacy Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only
Lasso di tempo: Up to approximately 21 days
|
The following events if considered drug related by the Investigator, will be considered a DLT: Grade 4 nonhematologic toxicity (not based on laboratory value); Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia associated with clinically significant bleeding; Nonhematologic AEs ≥Grade 3 with exceptions; Grade 3 or Grade 4 non-hematologic laboratory values if requires medical intervention, leads to hospitalization, persists for >1 week, or results in a Drug-induced Liver Injury with exceptions; Grade 3 or 4 febrile neutropenia; Study intervention - related toxicities that lead to discontinuation of study treatment during Cycle 1; Prolonged delay (>2 weeks) in initiating Cycles 2 due to treatment-related toxicity; Missing >25% of study intervention doses as a result of treatment-related AE during Cycle 1; Grade 5 toxicity. |
Up to approximately 21 days
|
|
Efficacy Phase: Number of Participants Who Experienced an Adverse Event (AE)
Lasso di tempo: Up to approximately 54 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 54 months
|
|
Efficacy Phase: Number of Participants Who Discontinued Study Intervention Due to an AE
Lasso di tempo: Up to approximately 24 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 24 months
|
|
Efficacy Phase: Prostate-Specific Antigen (PSA) response rate
Lasso di tempo: Up to approximately 54 months
|
PSA response is defined per prostate cancer working group (PCWG) criteria as a reduction in the PSA level of 50% or more from baseline measured at consecutive assessments at least 3 weeks apart. |
Up to approximately 54 months
|
|
Safety Lead-in Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only
Lasso di tempo: Up to approximately 21 days
|
The following events if considered drug related by the Investigator, will be considered a DLT: Grade 4 nonhematologic toxicity (not based on laboratory value); Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia associated with clinically significant bleeding; Nonhematologic AEs ≥Grade 3 with exceptions; Grade 3 or Grade 4 non-hematologic laboratory values if requires medical intervention, leads to hospitalization, persists for >1 week, or results in a Drug-induced Liver Injury with exceptions; Grade 3 or 4 febrile neutropenia; Study intervention - related toxicities that lead to discontinuation of study treatment during Cycle 1; Prolonged delay (>2 weeks) in initiating Cycles 2 due to treatment-related toxicity; Missing >25% of study intervention doses as a result of treatment-related AE during Cycle 1; Grade 5 toxicity. |
Up to approximately 21 days
|
|
Safety Lead-in Phase: Number of Participants Who Experienced an Adverse Event (AE) - Combination Arms Only
Lasso di tempo: Up to approximately 21 days
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 21 days
|
|
Safety Lead-in Phase: Number of Participants Who Discontinued Study Intervention Due to an AE - Combination Arms Only
Lasso di tempo: Up to approximately 21 days
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 21 days
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective Response Rate (ORR)
Lasso di tempo: Up to approximately 54 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per PCWG3-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented. |
Up to approximately 54 months
|
|
Radiographic Progression-Free Survival (rPFS)
Lasso di tempo: Up to approximately 54 months
|
rPFS is defined as the time from randomization to the first documented progressive disease (PD) per PCWG3-modified RECIST 1.1 based on BICR or death due to any cause, whichever occurred first. Per PCWG3-modified RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions or ≥2 new bone lesions was also considered PD. PCWG3-modified RECIST is similar to RECIST 1.1 with the exception that a confirmation assessment of PD (>4 weeks after the initial PD) is required for participants who remain on treatment following a documented PD per RECIST 1.1 and PCWG3 rules include new bone lesions. The rPFS per PCWG3-modified RECIST as assessed by BICR for all participants is presented. The nonparametric Kaplan-Meier method will be used to estimate the rPFS curve in each treatment arm |
Up to approximately 54 months
|
|
Overall Survival (OS)
Lasso di tempo: Up to approximately 54 months
|
Overall survival (OS) is defined as the time from randomization to death due to any cause. The nonparametric Kaplan-Meier method will be used to estimate the survival curves. |
Up to approximately 54 months
|
|
Duration of Response (DOR)
Lasso di tempo: Up to approximately 54 months
|
DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per PCWG3-modified RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of ≥ 2 new bone lesions is also considered PD. DOR as assessed by BICR is presented. The nonparametric Kaplan-Meier method will be used to estimate the DOR in each treatment arm. |
Up to approximately 54 months
|
|
Time from allocation/randomization to initiation of the first subsequent anticancer therapy (TFST)
Lasso di tempo: Up to approximately 54 months
|
TFST is defined as the time from randomization to initiation of the first subsequent anticancer therapy or death, whichever occurs first. The nonparametric Kaplan-Meier method will be used to estimate the TFST in each treatment arm. |
Up to approximately 54 months
|
|
Time to Prostate-Specific Antigen (PSA) Progression
Lasso di tempo: Up to approximately 54 months
|
Time to PSA progression is defined as the time from randomization to PSA progression. Participants without PSA progression will be censored at the last PSA assessment date. The PSA progression date is defined as the date of: 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, OR 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline. |
Up to approximately 54 months
|
|
Time to pain progression (TTPP)
Lasso di tempo: Up to approximately 54 months
|
The time from allocation/randomization to pain progression based on the Brief Pain Inventory-Short Form (BPI-SF) Item 3 "worst pain in 24 hours" and by the Analgesic Quantification Algorithm (AQA) score. |
Up to approximately 54 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Direttore dello studio: Medical Director, Merck Sharp & Dohme LLC
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Processi patologici
- Neoplasie genitali, maschio
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie genitali, maschio
- Malattie della prostata
- Malattie urogenitali maschili
- Processi neoplastici
- Condizioni patologiche, segni e sintomi
- Neoplasie prostatiche
- Metastasi neoplastica
- Neoplasie prostatiche resistenti alla castrazione
- Prodotti chimici organici
- Idrocarburi
- Cicloparaffins
- Idrocarburi, aliciclici
- Idrocarburi, ciclici
- Terpeni
- Taxoidi
- Ciclodecani
- Diterpenes
- Docetaxel
- Abiraterone
- Enzalutamide
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 2400-01A
- MK-2400-01A (Altro identificatore: MSD)
- U1111-1310-5406 (Identificatore di registro: UTN)
- IDeate-Prostate02 (Altro identificatore: MSD)
- 2024-516036-94-00 (Identificatore di registro: EU CT)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .